Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated by Analysts at

Equities research analysts at initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIXGet Free Report) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Trading Up 0.3 %

Shares of CPIX opened at $1.69 on Monday. The company has a current ratio of 1.62, a quick ratio of 1.21 and a debt-to-equity ratio of 0.36. The firm’s 50-day moving average is $1.56 and its two-hundred day moving average is $1.81. Cumberland Pharmaceuticals has a twelve month low of $1.43 and a twelve month high of $2.91. The firm has a market capitalization of $24.29 million, a P/E ratio of -13.00 and a beta of 0.32.

Cumberland Pharmaceuticals (NASDAQ:CPIXGet Free Report) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $0.15 earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 4.39% and a positive return on equity of 11.44%. The company had revenue of $10.89 million for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Cumberland Pharmaceuticals in the second quarter valued at approximately $133,000. Millennium Management LLC acquired a new position in shares of Cumberland Pharmaceuticals in the fourth quarter worth $46,000. True Capital Management purchased a new stake in shares of Cumberland Pharmaceuticals in the fourth quarter valued at $27,000. Renaissance Technologies LLC boosted its stake in shares of Cumberland Pharmaceuticals by 6.3% during the first quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after acquiring an additional 38,100 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in Cumberland Pharmaceuticals by 27.8% during the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after purchasing an additional 40,949 shares in the last quarter. 16.95% of the stock is currently owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

(Get Free Report)

Cumberland Pharmaceuticals, Inc is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex.

Featured Articles

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with's FREE daily email newsletter.